The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, VISA strains often harbor mutations in genes associated with cell wall biosynthesis and regulatory systems, such as walKR and rpoB [8,217,218].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Research works printed but not linked: 129
- Alexander, 2014, Intermediate-type vancomycin resistance (VISA) in genetically-distinct Staphylococcus aureus isolates is linked to specific, reversible metabolic alterations, PLoS ONE, 9, e97137, 10.1371/journal.pone.0097137 · DOI · Paper page
- Antony, 2014, Case series describing an outbreak of highly resistant vancomycin Staphylococcus aureus (possible VISA/VRSA) infections in orthopedic related procedures in Guatemala, Infect. Disord. Drug Targets, 14, 44, 10.2174/1871526514666140522115220 · doi:10.2174/1871526514666140522115220
- Atilano, 2010, Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in Staphylococcus aureus, Proc. Natl. Acad. Sci. U.S.A., 107, 18991, 10.1073/pnas.1004304107 · DOI · Paper page
- Bae, 2006, Allelic replacement in Staphylococcus aureus with inducible counter-selection, Plasmid, 55, 58, 10.1016/j.plasmid.2005.05.005 · DOI · Paper page
- Belcheva, 2009, DNA-binding activity of the vancomycin resistance associated regulator protein VraR and the role of phosphorylation in transcriptional regulation of the vraSR operon, Biochemistry, 48, 5592, 10.1021/bi900478b · DOI
- Beltramini, 2009, Modulation of cell wall structure and antimicrobial susceptibility by a Staphylococcus aureus eukaryote-like serine/threonine kinase and phosphatase, Infect. Immun., 77, 1406, 10.1128/IAI.01499-08 · DOI
- Berscheid, 2014, Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS, J. Antimicrob. Chemother., 69, 3190, 10.1093/jac/dku297 · DOI
- Bischoff, 2016, Stk1-mediated phosphorylation stimulates the DNA-binding properties of the Staphylococcus aureus SpoVG transcriptional factor, Biochem. Biophys. Res. Commun., 473, 1223, 10.1016/j.bbrc.2016.04.044 · DOI
- Boyle-Vavra, 2013, VraT/YvqF is required for methicillin resistance and activation of the VraSR regulon in Staphylococcus aureus, Antimicrob. Agents Chemother., 57, 83, 10.1128/AAC.01651-12 · DOI
- Cameron, 2012, Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus, J. Infect. Dis., 205, 1677, 10.1093/infdis/jis252 · DOI
- Campbell, 2012, An antibiotic that inhibits a late step in wall teichoic acid biosynthesis induces the cell wall stress stimulon in Staphylococcus aureus, Antimicrob. Agents Chemother., 56, 1810, 10.1128/AAC.05938-11 · DOI
- Canova, 2014, A novel mode of regulation of the Staphylococcus aureus Vancomycin-resistance-associated response regulator VraR mediated by Stk1 protein phosphorylation, Biochem. Biophys. Res. Commun., 447, 165, 10.1016/j.bbrc.2014.03.128 · DOI
- Chan, 2013, Staphylococcus aureus mutants lacking the LytR-CpsA-Psr family of enzymes release cell wall teichoic acids into the extracellular medium, J. Bacteriol., 195, 4650, 10.1128/JB.00544-13 · DOI
- Chen, 2015, Multiple pathways of cross-resistance to glycopeptides and daptomycin in persistent MRSA bacteraemia, J. Antimicrob. Chemother., 70, 2965, 10.1093/jac/dkv225 · DOI
- Chen, 2014, Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing, J. Antimicrob. Chemother., 69, 349, 10.1093/jac/dkt395 · DOI
- Chen, 2016, Transcriptional profiling of the two-component regulatory system VraSR in Staphylococcus aureus with low-level vancomycin resistance, Int. J. Antimicrob. Agents, 47, 362, 10.1016/j.ijantimicag.2016.02.003 · DOI
- Cluzel, 2010, The Staphylococcus aureus autoinducer-2 synthase LuxS is regulated by Ser/Thr phosphorylation, J. Bacteriol., 192, 6295, 10.1128/JB.00853-10 · DOI
- Cui, 2006, Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 50, 428, 10.1128/AAC.50.2.428-438.2006 · DOI · Paper page
- Cui, 2005, DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 49, 3404, 10.1128/AAC.49.8.3404-3413.2005 · DOI
- Cui, 2003, Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus, J. Clin. Microbiol., 41, 5, 10.1128/JCM.41.1.5-14.2003 · DOI · Paper page
- Cui, 2000, Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50, Antimicrob. Agents Chemother., 44, 2276, 10.1128/AAC.44.9.2276-2285.2000 · DOI · Paper page
- Cui, 2009, Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 1231, 10.1128/AAC.01173-08 · DOI
- Dayan, 2016, Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention, Expert Rev. Vaccines., 10.1080/14760584.2016.1179583 · DOI
- Débarbouillé, 2009, Characterization of a serine/threonine kinase involved in virulence of Staphylococcus aureus, J. Bacteriol., 191, 4070, 10.1128/JB.01813-08 · DOI
- Delauné, 2012, The WalKR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response, Infect. Immun., 80, 3438, 10.1128/IAI.00195-12 · DOI · Paper page
- Didelot, 2016, Within-host evolution of bacterial pathogens, Nat. Rev. Microbiol., 14, 150, 10.1038/nrmicro.2015.13 · DOI · Paper page
- Ding, 2014, Metabolic sensor governing bacterial virulence in Staphylococcus aureus, Proc. Natl. Acad. Sci. U.S.A., 111, E4981, 10.1073/pnas.1411077111 · DOI
- Dmitriev, 2004, Tertiary structure of Staphylococcus aureus cell wall murein, J. Bacteriol., 186, 7141, 10.1128/JB.186.21.7141-7148.2004 · DOI
- Donat, 2009, Transcriptome and functional analysis of the eukaryotic-type serine/threonine kinase PknB in Staphylococcus aureus, J. Bacteriol., 191, 4056, 10.1128/JB.00117-09 · DOI
- Dubrac, 2008, A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway, Mol. Microbiol., 70, 1307, 10.1111/j.1365-2958.2008.06483.x · DOI · Paper page
- Dubrac, 2007, New insights into the WalK/WalR (YycG/YycF) essential signal transduction pathway reveal a major role in controlling cell wall metabolism and biofilm formation in Staphylococcus aureus, J. Bacteriol., 189, 8257, 10.1128/JB.00645-07 · DOI · Paper page
- Ernst, 2011, Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids, Mol. Microbiol., 80, 290, 10.1111/j.1365-2958.2011.07576.x · DOI · Paper page
- Falord, 2012a, GraXSR proteins interact with the VraFG ABC transporter to form a five-component system required for cationic antimicrobial peptide sensing and resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 56, 1047, 10.1128/AAC.05054-11 · DOI · Paper page
- Falord, 2012b, Investigation of the Staphylococcus aureus GraSR regulon reveals novel links to virulence, stress response and cell wall signal transduction pathways, PLoS ONE, 6, e21323, 10.1371/journal.pone.0021323 · DOI · Paper page
- Fedtke, 2007, A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity, Mol. Microbiol., 65, 1078, 10.1111/j.1365-2958.2007.05854.x · DOI · Paper page
- Feng, 2013, Trapping and proteomic identification of cellular substrates of the ClpP protease in Staphylococcus aureus, J. Proteome Res., 12, 547, 10.1021/pr300394r · DOI
- Foucault, 2009, Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 2354, 10.1128/AAC.01702-08 · DOI
- Frees, 2014, Clp chaperones and proteases are central in stress survival, virulence and antibiotic resistance of Staphylococcus aureus, Int. J. Med. Microbiol., 304, 142, 10.1016/j.ijmm.2013.11.009 · DOI · Paper page
- Fridman, 2013, Two unique phosphorylation-driven signaling pathways crosstalk in Staphylococcus aureus to modulate the cell-wall charge: Stk1/Stp1 meets GraSR, Biochemistry, 52, 7975, 10.1021/bi401177n · DOI
- Gao, 2013, The RpoB H(4)(8)(1)Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus, J. Infect. Dis., 207, 929, 10.1093/infdis/jis772 · DOI
- Gardete, 2012, Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300, PLoS Pathog., 8, e1002505, 10.1371/journal.ppat.1002505 · DOI · Paper page
- Gardete, 2006, Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus, Antimicrob. Agents Chemother., 50, 3424, 10.1128/AAC.00356-06 · DOI · Paper page
- Graham, 2013, Trapping and identification of cellular substrates of the Staphylococcus aureus ClpC chaperone, J. Bacteriol., 195, 4506, 10.1128/JB.00758-13 · DOI
- Gründling, 2007, Genes required for glycolipid synthesis and lipoteichoic acid anchoring in Staphylococcus aureus, J. Bacteriol., 189, 2521, 10.1128/JB.01683-06 · DOI · Paper page
- Hanaki, 1998, Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50, J. Antimicrob. Chemother., 42, 199, 10.1093/jac/42.2.199 · DOI · Paper page
- Hartmann, 2013, Catabolite control protein E (CcpE) is a LysR-type transcriptional regulator of tricarboxylic acid cycle activity in Staphylococcus aureus, J. Biol. Chem., 288, 36116, 10.1074/jbc.M113.516302 · DOI
- Hattangady, 2015, Genomic, transcriptomic and metabolomic studies of two well-characterized, laboratory-derived vancomycin-intermediate Staphylococcus aureus strains derived from the same parent strain, Antibiotics (Basel), 4, 76, 10.3390/antibiotics4010076 · DOI
- Hiramatsu, 1997a, Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin, Lancet, 350, 1670, 10.1016/S0140-6736(97)07324-8 · DOI · Paper page
- Hiramatsu, 1997b, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J. Antimicrob. Chemother., 40, 135, 10.1093/jac/40.1.135 · DOI · Paper page
- Horne, 2009, Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA, Antimicrob. Agents Chemother., 53, 3447, 10.1128/AAC.01365-08 · DOI
- Howden, 2011, Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR, PLoS Pathog., 7, e1002359, 10.1371/journal.ppat.1002359 · DOI · Paper page
- Howden, 2014, The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA, Infect. Genet. Evol., 21, 575, 10.1016/j.meegid.2013.03.047 · DOI · Paper page
- Howden, 2008, Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus, Antimicrob. Agents Chemother., 52, 3755, 10.1128/AAC.01613-07 · DOI
- Hu, 2015, Mechanism of reduced vancomycin susceptibility conferred by walK mutation in community-acquired methicillin-resistant Staphylococcus aureus strain MW2, Antimicrob. Agents Chemother., 59, 1352, 10.1128/AAC.04290-14 · DOI
- Hübscher, 2009, MsrR contributes to cell surface characteristics and virulence in Staphylococcus aureus, FEMS Microbiol. Lett., 295, 251, 10.1111/j.1574-6968.2009.01603.x · DOI
- Ingavale, 2003, Characterization of RAT, an autolysis regulator in Staphylococcus aureus, Mol. Microbiol., 48, 1451, 10.1046/j.1365-2958.2003.03503.x · DOI
- Ishii, 2015, Phenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis, Sci. Rep., 5, 17092, 10.1038/srep17092 · DOI
- Jansen, 2007, Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus, Int. J. Med. Microbiol., 297, 205, 10.1016/j.ijmm.2007.02.002 · DOI · Paper page
- Jousselin, 2013, The Staphylococcus aureus thiol/oxidative stress global regulator Spx controls trfA, a gene implicated in cell wall antibiotic resistance, Antimicrob. Agents Chemother., 57, 3283, 10.1128/AAC.00220-13 · DOI
- Kahne, 2005, Glycopeptide and lipoglycopeptide antibiotics, Chem. Rev., 105, 425, 10.1021/cr030103a · DOI · Paper page
- Kajimura, 2005, Identification and molecular characterization of an N-acetylmuramyl-L-alanine amidase Sle1 involved in cell separation of Staphylococcus aureus, Mol. Microbiol., 58, 1087, 10.1111/j.1365-2958.2005.04881.x · DOI · Paper page
- Katayama, 2009, Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem, Antimicrob. Agents Chemother., 53, 3190, 10.1128/AAC.00834-08 · DOI
- Katayama, 2016, Complete reconstitution of the vancomycin-intermediate Staphylococcus aureus phenotype of strain Mu50 in vancomycin-susceptible S. aureus, Antimicrob. Agents Chemother., 60, 3730, 10.1128/AAC.00420-16 · DOI · Paper page
- Kato, 2010, Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR, J. Antimicrob. Chemother., 65, 37, 10.1093/jac/dkp394 · DOI
- Kato, 2008, Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance, Int. J. Antimicrob. Agents, 31, 64, 10.1016/j.ijantimicag.2007.08.012 · doi:10.1016/j.ijantimicag.2007.08.012
- Kuroda, 2003, Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus, Mol. Microbiol., 49, 807, 10.1046/j.1365-2958.2003.03599.x · DOI · Paper page
- Kuroda, 2000, Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method, Biochem. Biophys. Res. Commun., 269, 485, 10.1006/bbrc.2000.2277 · DOI · Paper page
- Leiba, 2012, A novel mode of regulation of the Staphylococcus aureus catabolite control protein A (CcpA) mediated by Stk1 protein phosphorylation, J. Biol. Chem., 287, 43607, 10.1074/jbc.M112.418913 · DOI
- Levine, 2006, Vancomycin: a history, Clin. Infect. Dis., 42, S5, 10.1086/491709 · DOI · Paper page
- Liebeke, 2010, A metabolomic view of Staphylococcus aureus and its ser/thr kinase and phosphatase deletion mutants: involvement in cell wall biosynthesis, Chem. Biol., 17, 820, 10.1016/j.chembiol.2010.06.012 · DOI
- Limbago, 2014, Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States, J. Clin. Microbiol., 52, 998, 10.1128/JCM.02187-13 · DOI · Paper page
- Ling, 2014, A new antibiotic kills pathogens without detectable resistance, Nature, 517, 455, 10.1038/nature14098 · DOI · Paper page
- Liu, 2016, SpoVG regulates cell wall metabolism and oxacillin resistance in methicillin-resistant Staphylococcus aureus strain N315, Antimicrob. Agents Chemother., 60, 3455, 10.1128/AAC.00026-16 · doi:10.1128/aac.00026-16
- Majcherczyk, 2008, Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis, Microb. Pathog., 45, 408, 10.1016/j.micpath.2008.09.003 · DOI
- Maki, 2004, tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 48, 1953, 10.1128/AAC.48.6.1953-1959.2004 · DOI
- Manna, 2004, Identification of sarV (SA2062), a new transcriptional regulator, is repressed by SarA and MgrA (SA0641) and involved in the regulation of autolysis in Staphylococcus aureus, J. Bacteriol., 186, 5267, 10.1128/JB.186.16.5267-5280.2004 · DOI · Paper page
- Matsuo, 2014, Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3, Antimicrob. Agents Chemother., 57, 5843, 10.1128/AAC.00425-13 · DOI
- Matsuo, 2011, Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3, Antimicrob. Agents Chemother., 55, 4188, 10.1128/AAC.00398-11 · DOI
- McAleese, 2006, Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin, J. Bacteriol., 188, 1120, 10.1128/JB.188.3.1120-1133.2006 · DOI · Paper page
- McCallum, 2011, Mutational analyses of open reading frames within the vraSR operon and their roles in the cell wall stress response of Staphylococcus aureus, Antimicrob. Agents Chemother., 55, 1391, 10.1128/AAC.01213-10 · DOI
- McEvoy, 2013, Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression, Antimicrob. Agents Chemother., 57, 3240, 10.1128/AAC.00279-13 · DOI
- Meehl, 2007, Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 51, 2679, 10.1128/AAC.00209-07 · DOI · Paper page
- Melo-Cristino, 2013, First case of infection with vancomycin-resistant Staphylococcus aureus in Europe, Lancet, 382, 205, 10.1016/S0140-6736(13)61219-2 · DOI
- Moellering, 2006, Vancomycin: a 50-year reassessment, Clin. Infect. Dis., 42, S3, 10.1086/491708 · DOI · Paper page
- Moravvej, 2013, Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains, Int. J. Antimicrob. Agents, 42, 370, 10.1016/j.ijantimicag.2013.06.004 · doi:10.1016/j.ijantimicag.2013.06.004
- Murray, 2000, Vancomycin-resistant enterococcal infections, N. Engl. J. Med., 342, 710, 10.1056/NEJM200003093421007 · DOI · Paper page
- Mwangi, 2007, Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing, Proc. Natl. Acad. Sci. U.S.A., 104, 9451, 10.1073/pnas.0609839104 · DOI · Paper page
- Nannini, 2010, Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus, Curr. Opin. Pharmacol., 10, 516, 10.1016/j.coph.2010.06.006 · DOI · Paper page
- Nelson, 2007, Vancomycin-intermediate Staphylococcus aureus strains have impaired acetate catabolism: implications for polysaccharide intercellular adhesin synthesis and autolysis, Antimicrob. Agents Chemother., 51, 616, 10.1128/AAC.01057-06 · DOI · Paper page
- Neoh, 2008, Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance, Antimicrob. Agents Chemother., 52, 45, 10.1128/AAC.00534-07 · DOI
- Nordmann, 2007, Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010, Curr. Opin. Microbiol., 10, 436, 10.1016/j.mib.2007.07.004 · DOI · Paper page
- Ohlsen, 2010, The impact of serine/threonine phosphorylation in Staphylococcus aureus, Int. J. Med. Microbiol., 300, 137, 10.1016/j.ijmm.2009.08.016 · DOI
- Passalacqua, 2012, A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin, Antimicrob. Agents Chemother., 56, 5212, 10.1128/AAC.05770-11 · DOI
- Peleg, 2009, Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection, J. Infect. Dis., 199, 532, 10.1086/596511 · DOI · Paper page
- Pereira, 2007, Fluorescence ratio imaging microscopy shows decreased access of vancomycin to cell wall synthetic sites in vancomycin-resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 51, 3627, 10.1128/AAC.00431-07 · DOI
- Pillai, 2009, Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus, Clin. Infect. Dis., 49, 1169, 10.1086/605636 · DOI
- Reichmann, 2014, Differential localization of LTA synthesis proteins and their interaction with the cell division machinery in Staphylococcus aureus, Mol. Microbiol., 92, 273, 10.1111/mmi.12551 · DOI
- Renzoni, 2011, Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus, PLoS ONE, 6, e21577, 10.1371/journal.pone.0021577 · DOI
- Renzoni, 2009, Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus, Antimicrob. Agents Chemother., 53, 903, 10.1128/AAC.01287-08 · DOI
- Reynolds, 2012, Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07, J. Antimicrob. Chemother., 67, 2912, 10.1093/jac/dks324 · doi:10.1093/jac/dks324
- Robert, 2006, Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002, J. Antimicrob. Chemother., 57, 506, 10.1093/jac/dki486 · DOI
- Rubinstein, 2014, Vancomycin revisited - 60 years later, Front. Public Health, 2, 10.3389/fpubh.2014.00217 · DOI · Paper page
- Ruggiero, 2012, Bacterial cell division regulation by Ser/Thr kinases: a structural perspective, Curr. Protein Pept. Sci., 13, 756, 10.2174/138920312804871201 · DOI
- Rybak, 2005, Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin, Diagn. Microbiol. Infect. Dis., 51, 119, 10.1016/j.diagmicrobio.2004.09.005 · DOI
- Sader, 2009, Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006, Antimicrob. Agents Chemother., 53, 4127, 10.1128/AAC.00616-09 · DOI
- Samanta, 2014, The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains, Antimicrob. Agents Chemother., 58, 6685, 10.1128/AAC.03280-14 · DOI
- Sambanthamoorthy, 2006, Identification and characterization of msa (SA1233), a gene involved in expression of SarA and several virulence factors in Staphylococcus aureus, Microbiology (Reading Engl)., 152, 2559, 10.1099/mic.0.29071-0 · DOI
- Schlag, 2010, Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl, Mol. Microbiol., 75, 864, 10.1111/j.1365-2958.2009.07007.x · DOI · Paper page
- Schulthess, 2009, Functional characterization of the sigmaB-dependent yabJ-spoVG operon in Staphylococcus aureus: role in methicillin and glycopeptide resistance, Antimicrob. Agents Chemother., 53, 1832, 10.1128/AAC.01255-08 · DOI
- Schumacher, 2007, Structural mechanism for the fine-tuning of CcpA function by the small molecule effectors glucose 6-phosphate and fructose 1,6-bisphosphate, J. Mol. Biol., 368, 1042, 10.1016/j.jmb.2007.02.054 · DOI
- Schwaber, 2003, Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia, Emerging Infect. Dis., 9, 657, 10.3201/eid0906.030001 · DOI
- Seidl, 2009, Effect of a glucose impulse on the CcpA regulon in Staphylococcus aureus, BMC Microbiol., 9, 95, 10.1186/1471-2180-9-95 · DOI · Paper page
- Seidl, 2006, Staphylococcus aureus CcpA affects virulence determinant production and antibiotic resistance, Antimicrob. Agents Chemother., 50, 1183, 10.1128/AAC.50.4.1183-1194.2006 · DOI · Paper page
- Sengupta, 2012, Chromatin immunoprecipitation identifies genes under direct VraSR regulation in Staphylococcus aureus, Can. J. Microbiol., 58, 703, 10.1139/w2012-043 · doi:10.1139/w2012-043
- Shang, 2016, Comparative fitness and determinants for the characteristic drug resistance of ST239-MRSA-III-t030 and ST239-MRSA-III-t037 strains isolated in China, Microb. Drug Resist., 22, 185, 10.1089/mdr.2015.0226 · DOI
- Shoji, 2011, walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus, Antimicrob. Agents Chemother., 55, 3870, 10.1128/AAC.01563-10 · DOI
- Sieradzki, 2003, Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus, J. Bacteriol., 185, 7103, 10.1128/JB.185.24.7103-7110.2003 · DOI · Paper page
- Sun, 2012, Protein cysteine phosphorylation of SarA/MgrA family transcriptional regulators mediates bacterial virulence and antibiotic resistance, Proc. Natl. Acad. Sci. U.S.A., 109, 15461, 10.1073/pnas.1205952109 · DOI · Paper page
- Sun, 2013, Modulation of cell wall synthesis and susceptibility to vancomycin by the two-component system AirSR in Staphylococcus aureus NCTC8325, BMC Microbiol., 13, 286, 10.1186/1471-2180-13-286 · DOI
- Tamber, 2010, Role of PknB kinase in antibiotic resistance and virulence in community-acquired methicillin-resistant Staphylococcus aureus strain USA300, Infect. Immun., 78, 3637, 10.1128/IAI.00296-10 · DOI
- Utaida, 2006, Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50, Antimicrob. Agents Chemother., 50, 1541, 10.1128/AAC.50.4.1541-1545.2006 · DOI
- Van Hal, 2014, In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale?, J. Antimicrob. Chemother., 69, 363, 10.1093/jac/dkt354 · DOI
- Vidaillac, 2013, Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus, J. Infect. Dis., 208, 67, 10.1093/infdis/jit127 · DOI
- Walters, 2015, Vancomycin-resistant Staphylococcus aureus - Delaware, 2015, Morb. Mortal. Wkly. Rep., 64, 1056, 10.15585/mmwr.mm6437a6 · doi:10.15585/mmwr.mm6437a6
- Yamakawa, 2012, Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: a retrospective study, J. Infect. Chemother., 18, 406, 10.1007/s10156-011-0330-2 · DOI
- Zhang, 2013, First report of a sequence type 239 vancomycin-intermediate Staphylococcus aureus isolate in Mainland China, Diagn. Microbiol. Infect. Dis., 77, 64, 10.1016/j.diagmicrobio.2013.06.008 · DOI
- Zhou, 2012, Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China, BMC Microbiol., 12, 240, 10.1186/1471-2180-12-240 · DOI
- Zhu, 2013, pSK41-like plasmid is necessary for Inc18-like vanA plasmid transfer from Enterococcus faecalis to Staphylococcus aureus in vitro, Antimicrob. Agents Chemother., 57, 212, 10.1128/AAC.01587-12 · DOI
- Zhuo, 2013, Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006-2011 in China, Int. J. Antimicrob. Agents, 41, 578, 10.1016/j.ijantimicag.2013.02.014 · doi:10.1016/j.ijantimicag.2013.02.014
Cited by
Cong, Y., Yang, S., & Rao, X. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2019.10.005 · Cited by 527
Self-citationAntibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Hu, Q., Peng, H., & Rao, X.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2016-10-13
- Volume
- 7
- ISSN
- 1664-302X
- Cited by
- 132
- References
- 1
- Funders
- National Natural Science Foundation of China (81471993, 81672071)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.